Published in Brain on January 01, 1999
Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients | NCT01555684
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis | NCT00321568
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 5.35
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol (2012) 3.07
A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. Neuroimage (2009) 3.07
The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med (2006) 2.42
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci (2008) 1.90
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry (2014) 1.65
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol (2010) 1.54
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology (2014) 1.46
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain (2008) 1.34
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology (2009) 1.24
Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol (2008) 1.22
The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol (2008) 1.16
A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology (2011) 1.16
Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 1.16
CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage (2010) 1.15
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed (2010) 1.13
Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg Psychiatry (2003) 1.11
Neurogenesis in the chronic lesions of multiple sclerosis. Brain (2008) 1.10
Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol (2010) 1.10
High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients. J Neuroimaging (2009) 1.09
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08
Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 1.07
Localization of grey matter atrophy in early RRMS : A longitudinal study. J Neurol (2006) 1.06
NG2 cells (polydendrocytes): listeners to the neural network with diverse properties. Glia (2014) 1.04
Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One (2013) 1.04
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis. Neuroimage (2011) 1.03
Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult Scler (2011) 1.01
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol (2012) 1.00
DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Mult Scler Int (2013) 0.99
Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains. J Neuropathol Exp Neurol (2014) 0.99
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging (2011) 0.97
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol (2005) 0.96
Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 0.95
T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 0.94
Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci (2012) 0.94
Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol (2012) 0.94
Venous hemodynamics in neurological disorders: an analytical review with hydrodynamic analysis. BMC Med (2013) 0.94
Cognitive dysfunction in multiple sclerosis. Front Neurol (2012) 0.94
Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis. Neuropsychol Rev (2008) 0.93
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.91
Multiple sclerosis: autoimmunity and viruses. Curr Opin Rheumatol (2013) 0.89
Axonal damage in multiple sclerosis. Mt Sinai J Med (2011) 0.87
Brain metabolite proton T2 mapping at 3.0 T in relapsing-remitting multiple sclerosis. Radiology (2010) 0.86
Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. J Cereb Blood Flow Metab (2014) 0.85
Advances in understanding gray matter pathology in multiple sclerosis: are we ready to redefine disease pathogenesis? BMC Neurol (2012) 0.84
Cortical lesions and cognitive impairment in multiple sclerosis. Neurol Sci (2010) 0.84
Hla-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice. J Clin Invest (2000) 0.84
Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. Prostaglandins Leukot Essent Fatty Acids (2011) 0.84
Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. PLoS One (2013) 0.83
Advanced MRI in multiple sclerosis: current status and future challenges. Neurol Clin (2011) 0.83
Cortical injury in multiple sclerosis; the role of the immune system. BMC Neurol (2011) 0.83
Recurrent optic neuromyelitis with multiple endocrinopathies and autoimmune disorders. J Neurol (2002) 0.83
Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med (2008) 0.82
Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced MS mouse model. PLoS One (2012) 0.82
Cortical thinning in the anterior cingulate cortex predicts multiple sclerosis patients' fluency performance in a lateralised manner. Neuroimage Clin (2015) 0.82
Progressive multiple sclerosis and gray matter pathology: an MRI perspective. Mt Sinai J Med (2011) 0.81
Removal of cerebrospinal fluid partial volume effects in quantitative magnetization transfer imaging using a three-pool model with nonexchanging water component. Magn Reson Med (2014) 0.81
Comparison of double inversion recovery and conventional magnetic resonance brain imaging in patients with multiple sclerosis and relations with disease disability. Neuroradiol J (2013) 0.81
Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination. Acta Neuropathol (2014) 0.81
Normal appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. PLoS One (2014) 0.80
Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach. Ann Indian Acad Neurol (2009) 0.80
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Mult Scler Int (2013) 0.80
The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis. J Interferon Cytokine Res (2011) 0.80
Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics (2016) 0.79
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Gene expression profiling in multiple sclerosis brain. Neurobiol Dis (2010) 0.79
Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. Mult Scler (2015) 0.79
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol (2016) 0.79
BDNF Val66Met polymorphism and brain volumes in multiple sclerosis. Neurol Sci (2010) 0.78
Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. Neurol Sci (2011) 0.78
A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. J Neurol (2007) 0.77
Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol (2016) 0.77
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (1999) 0.77
Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. Neuroimage Clin (2015) 0.76
Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells. Sci Rep (2015) 0.76
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study. Mult Scler Int (2015) 0.76
Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2007) 0.76
Neuronopathy in the motor neocortex in a chronic model of multiple sclerosis. J Neuropathol Exp Neurol (2014) 0.75
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol (2016) 0.75
A Case of Cortical Multiple Sclerosis. Noro Psikiyatr Ars (2014) 0.75
Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75
Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study. Neuropsychiatr Dis Treat (2016) 0.75
Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS. PLoS One (2016) 0.75
The Neurophysiologist Perspective into MS Plasticity. Front Neurol (2015) 0.75
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis. PLoS One (2016) 0.75
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Measles-virus antibody and antigen in subacute sclerosing panencephalitis. Lancet (1967) 5.44
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Chronic central nervous system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects Study Group. Lancet (1991) 4.07
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Environmental tobacco smoke and absenteeism related to respiratory illness in schoolchildren. Am J Epidemiol (2003) 2.23
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol (2004) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A (2000) 2.11
Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. Thorax (2000) 2.06
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Regional DTI differences in multiple sclerosis patients. Neuroimage (2008) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Mixed glioneuronal tumour of the fourth ventricle with prominent rosette formation. Neuropathol Appl Neurobiol (2006) 1.88
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology (2010) 1.88
Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol (1995) 1.87
The heritability and genetics of frontotemporal lobar degeneration. Neurology (2009) 1.86
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci (1979) 1.73
MR venography of multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.72
Hippocampal atrophy in Alzheimer disease: age matters. Neurology (2006) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia (2006) 1.66
Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci (2011) 1.66
Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol (2010) 1.66
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology (2004) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 1.63
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet (1991) 1.62
Association between air pollution and lung function growth in southern California children. Am J Respir Crit Care Med (2000) 1.60
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Corpora amylacea in hippocampal sclerosis. J Neurol Neurosurg Psychiatry (1997) 1.60
Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology (2002) 1.60
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol (2009) 1.60
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
The effects of ambient air pollution on school absenteeism due to respiratory illnesses. Epidemiology (2001) 1.57
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain (2001) 1.56
Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus (2000) 1.55
Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol (2001) 1.54
Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
The predictive value of 3D time-of-flight MR angiography in assessment of brain arteriovenous malformation obliteration after radiosurgery. AJNR Am J Neuroradiol (2011) 1.53
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain (1998) 1.52
A theoretical basis for investigating ambient air pollution and children's respiratory health. Environ Health Perspect (1999) 1.52
Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.50
Microwave antigen retrieval for immunocytochemistry on formalin-fixed, paraffin-embedded post-mortem CNS tissue. J Pathol (1995) 1.50
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 1.50
Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann Surg (1999) 1.49
Glutathione-S-transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children. Thorax (2008) 1.48
Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol (2007) 1.48
Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr (2001) 1.47
White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology (2004) 1.47
Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology (2004) 1.46
FMRI of visual encoding: reproducibility of activation. Hum Brain Mapp (2000) 1.46
Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol (2003) 1.44
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol (1992) 1.44
A multidisciplinary team approach to skull base chordomas. J Neurosurg (2001) 1.44
Semantic dementia with ubiquitin-positive tau-negative inclusion bodies. Brain (2000) 1.43
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci (1994) 1.43
Patient-ventilator flow dyssynchrony: flow-limited versus pressure-limited breaths. Crit Care Med (1997) 1.42
MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med (2005) 1.42
Familial adult-onset muscular dystrophy with leukoencephalopathy. Ann Neurol (1992) 1.40
Pesticide illness surveillance: the Nicaraguan experience. Bull Pan Am Health Organ (1988) 1.40